Why transfusions and medical procedures once carried a risk they no longer do — and what that means for people looking back at their own history.
In sequence
- Virus unidentifiedno test possible; risk to transfusion recipients during this period was real and invisible
- Virus characterisedblood-screening tests rapidly developed and introduced
- Screening standard in high-income countriestransfusion risk drops sharply; residual risk in settings without consistent screening
When the Blood Supply Was Unscreened
For much of the twentieth century, donated blood was not tested for hepatitis C. It could not be, because the virus had not yet been identified, and without identification there was no test to run. Blood transfusions, surgical procedures involving blood products, and certain long-term medical treatments — dialysis among them — all took place in an era when what we now call hepatitis C was circulating silently and invisibly through medical systems that had no means of detecting it.
This is not a story of negligence. It is a story of what medicine could and could not do with the science available at the time. The virus itself was known to exist — clinicians observed a form of hepatitis that was neither type A nor type B — but its genetic identity remained unresolved. Once researchers isolated and characterised the virus, the path to a reliable blood-screening test opened quickly. Within a short time of that identification, blood services in many countries introduced routine screening of donated blood, and the risk profile of transfusion changed sharply.
The practical consequence is that the window of elevated transfusion risk sits in the past. Blood donated and transfused after screening became standard in a given country carries a dramatically lower risk than blood from the unscreened era. Someone who received a transfusion, underwent major surgery, or was treated with pooled blood products before screening was introduced in their country may have been exposed to the virus without anyone — patient, clinician, or blood-bank technician — being aware of it at the time.
What Procedures Carried Risk, and Why
The reason transfusions were an effective route of transmission comes down to the basic biology of the virus: hepatitis C spreads through blood-to-blood contact, and a transfusion is, by definition, an introduction of another person's blood into your body. If a donor was carrying the virus and had not been screened, the recipient received the virus along with the donated blood.
The same logic applied to clotting factors — concentrated blood products derived from pooled donations and used to treat conditions such as haemophilia. Because these products were prepared from the combined donations of many individuals, a single infected donor could, in theory, contaminate a large batch. People who received clotting factor concentrates during the unscreened era faced a particularly concentrated exposure risk for this reason.
Haemodialysis — the process of filtering blood outside the body for people whose kidneys cannot perform that function — also carried risk in settings where equipment was shared or infection-control protocols were less rigorous than they later became. The repeated, session-after-session nature of dialysis meant that any gap in prevention could be significant.
Organ transplantation from unscreened donors was another route, though a less common one simply because transplants affect far fewer people than transfusions or dialysis. Medical injections with shared or inadequately sterilised equipment — a problem that was more widespread in healthcare settings of earlier decades and remains a concern in parts of the world where sterile single-use equipment is not consistently available — round out the main historical medical pathways.
None of these routes depends on anything the recipient did or chose. They reflect the state of medical knowledge and infrastructure at a particular moment in history.
Why This Matters Now
Hepatitis C typically produces no noticeable symptoms for years, sometimes decades, after infection. Someone who acquired the virus through a procedure performed long ago may have had no sign of it. This is one reason that testing — prompted by a clinician, a result letter, or a person's own awareness of past medical history — sometimes surfaces an infection that has been present, quietly, for a very long time.
The historical context matters for a specific, practical reason: it helps explain why a positive result or a referral for further testing does not necessarily point to anything recent. For people who are trying to make sense of how an exposure might have occurred, knowing that certain medical procedures once carried risk that they no longer do is part of the picture. It locates the possibility in a specific chapter of medical history rather than leaving it unexplained.
It is also worth noting that the picture varies by country. Screening was introduced at different times in different national blood services, and the state of infection-control infrastructure varied widely. Someone who received medical care in a country where screening arrived later, or where sterile equipment was inconsistently available, may face a different historical risk profile than someone treated exclusively in a country with early, well-resourced screening programmes. A clinician with knowledge of both the patient's medical history and their country of care is better placed than any written resource to interpret what that history means in a specific case.
Understanding the history does not change the biology, but it can change the feeling of bewilderment that sometimes accompanies an unexpected result. The question of how this happened often has a clear, non-mysterious answer — one rooted in what medicine was able to do, and not yet able to do, in a particular time and place.
General information only — not medical advice. Not affiliated with any clinic, laboratory, charity, campaign or pharmaceutical company. If you have questions about your own health, speak to a qualified clinician.